{"name":"Numab Therapeutics AG","slug":"numab-therapeutics-ag","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxOSlZzOG9iOUliUVZNSzBCTXBuZV9IcXJZTUlnejVjSG5nWmhDeE9GeFUyR2QzVEtQeGJ5c210ZGptU2Y4RFEzMlpCWXJkMHRZb0NhT3BTMGNRcmdVYVg0M2ZmVS1vUHlBVEl0WWpoSEp4Y211TWU3VkxsX0d2UUMzY3RxdGNHcU9Jc19rWURNVzVoalRDTVlEck4xamhEb0Y4RTZfRFVZNm9nNGdlR2RwbGNUUy1MekVIM2xTRkNXd1FhQW1sOTVNRkJnWFcyeVB3UjFIQ1lESWl6QWZaZks5R01LVFVkTUQ5ZGhxLW9iUWxsSkdDaUxBYkdvQQ?oc=5","date":"2026-02-02","type":"pipeline","source":"GlobeNewswire","summary":"Sparrow Appoints Biopharmaceutical Industry Veteran, Carlo Incerti, M.D. to its Board of Directors - GlobeNewswire","headline":"Sparrow Appoints Biopharmaceutical Industry Veteran, Carlo Incerti, M.D. to its Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOZ2tHc0xnN2FXTTN2NXFRdUIwaXhCdDRkS1VjOExobG9ZRlFWa1JKNXNqbEFJMW1iV3pfUElHekFBSnd3M21nSmxxMEozQXlTbldvZzVNRzNoSGo3TFRCSUUzcEs2TTdfNWpnNVVjVXdYZllLaFF4RGFIbkljblNoNzVFNk95aTZYQ05PZjd5UEp1ZXVqRE54WVhLZ3Q?oc=5","date":"2025-09-09","type":"pipeline","source":"Yahoo Finance","summary":"Numab Therapeutics Announces Leadership Transition and Appoints Angehrn Pavik as Chief Executive Officer - Yahoo Finance","headline":"Numab Therapeutics Announces Leadership Transition and Appoints Angehrn Pavik as Chief Executive Officer","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-01-09","type":"pipeline","source":"The Manila Times","summary":"Numab Therapeutics Announces Series C Extension to CHF 180 Million, Completing Oversubscribed CHF 50 Million Financing - The Manila Times","headline":"Numab Therapeutics Announces Series C Extension to CHF 180 Million, Completing Oversubscribed CHF 50 Million Financing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AJBVV95cUxPT1pOejRIWE8taEd6eGJPQU1PS0VxajFOdUlyZ042am1JdVU0NzUwSV82QWlQZTRpbGhhZWdqRFFqRDJFTVhlcEVvOEM2UU5kWWdJdGc2M2x5dzhqTEtZQlcxN0FpdW1qR2c5eVBuVzNJUUxWQ25xQVUtbm85c2xIa3BGd0EtMEZhZng0a19KdzI4WmpaREFUNEtVOWFWeTZYQXRmZEJHNVZreTlXS3RLX09qanJvVjFMYVFiQkVKU1V6Rzd4bzlUYkxWTDFOSkxjV1loanRuQUh4YzRtZVg5TXVZekpuXzF1dUcwTF90TWlseE1KMkpOSjdRMzQ3aVZZOVVoMWJ0b1pHR1YtaG81TEhfLXRfNURGVmpOSWdnMlh3ZXJkblEzLUlwMUNVZ3ZacWJkU3hBb3hWZDI5TDJwd2NqUmQwbkh3ZmswNnZDWjFuandi?oc=5","date":"2024-11-15","type":"pipeline","source":"GlobeNewswire","summary":"Numab Therapeutics and Kaken Pharmaceutical Enter - GlobeNewswire","headline":"Numab Therapeutics and Kaken Pharmaceutical Enter","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQUnRERElsMElTa3hNSXI0dllLdnhVTE55TmZJNy1Eb0dvdVNUbVVSc2JRel9yX2luQjRrSEU1eXN4LVJsZHBQM2JvR2dRdklTTkJfaDJ4Z1ZySnhNSGxNY0xaX3EwdEYybkNXdWM5Y3FGYnM0cHE1ZGpMZWNwVGd6OFhNNVNleGpKSkFvQU85cGE0N1B5dlR3azIwOEdteU1IYmZlLTBvX05sSkZTcHpB?oc=5","date":"2024-11-15","type":"deal","source":"fiercebiotech.com","summary":"Biotechs behind J&J-bought Yellow Jersey partner on another immunology asset - fiercebiotech.com","headline":"Biotechs behind J&J-bought Yellow Jersey partner on another immunology asset","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNd0FON2tnWHFpTGJtQ3lMZW5OTTBOQUluNll4YkxfRlJ3TFE4M2RfUm10bjVJM3dfb2ZCOHhkMDNtb1QwMmVJenVJNmFwY0phd2JOSXBLQWQ3OXFqb0psbU9idzNkNFRpV1h4YW9ZUGhvWkR2SXZ6ZXprT0FSNHowVWFXV1pTajVQejdXejllQkhIbTN1SFE?oc=5","date":"2024-05-31","type":"pipeline","source":"Switzerland Global Enterprise (S-GE)","summary":"Numab Therapeutics sells subsidiary to Johnson & Johnson - Switzerland Global Enterprise (S-GE)","headline":"Numab Therapeutics sells subsidiary to Johnson & Johnson - Switzerland Global Enterprise (S-GE)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxQeG9pRDd3NVFSRjFrMjdsdVFWMUhuWm0yWUVpWm1YdWM0ZFJNMGU1SFZsSG5ReXkwSGFKd3BtejAtd1ZGNDVKRzhGVGRYbTRHUHctV3Jxb2t4TS1xOTREWVBjdEsxZDRqeU5SOXotX1k0WWg2QVROT1JHUWQ0UTBSWGxVUkJnM293U2cwQjVFVk1jc3NiaUctZWZKYjUxby1jQmVyLXFTWUgxRWlyUVpFTVFkRDVLUTVWVHc?oc=5","date":"2024-05-28","type":"pipeline","source":"Pharmaceutical Technology","summary":"J&J expands atopic dermatitis scope with $1.25bn Numab antibody purchase - Pharmaceutical Technology","headline":"J&J expands atopic dermatitis scope with $1.25bn Numab antibody purchase","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQQWg0cVdDa3BDRmhNUlVLcmh6cnJJemtrbnctTHZmUVcyWmVEZFNsZjBIYVRLSW81MDBvRnB0U1hwQjRZNTVNRnNZMjV2dTNJcHBCWVdCQVg5ekVuZ3VsM1NSc1dRUlp1eWJCYnJqQzRkUGJJcW5fZGI1VFFTbkgxYmVNRWttMEthaXlzYjZ3bFVaMXdxQmJ4WE5hLTkxMTIzUmlqSnZR?oc=5","date":"2024-05-28","type":"deal","source":"BioCentury","summary":"J&J adds bispecific for atopic dermatitis via deal with Numab - BioCentury","headline":"J&J adds bispecific for atopic dermatitis via deal with Numab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxQR21abEVhQXhnVmtRc1plLUtDa3IxQVUyUk5ZR1Q3SnU1Q0FpenJJOGRHdjJnMUQxSTRBXzZnU0pMbmxHZGhtR1ljNjM2a1pmT1hTTVF3bDN1c1VUb1EtT2ZZUDFzQmMyZ0dqUFgxS1ViR0M4ejJCT1hOZlRDWHRwVDdvX3hQclBzM0dIZHFQMFE1SkY0cHhRRmt0R3lJSFAtM0N5R05vcXNWZGtSTnc5V0NwZHNNeFJVMXZES29CX3o4d190SVVQXzd1VVczYjhaaW1QQWZFVQ?oc=5","date":"2023-07-21","type":"pipeline","source":"BioWorld News","summary":"Mage Biologics receives investment to develop oral monoclonal antibody targeting ulcerative colitis - BioWorld News","headline":"Mage Biologics receives investment to develop oral monoclonal antibody targeting ulcerative colitis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxOOF9ySVFOb1ZSN0tJQkdJenI5VXVoeWMtQ3ZUVGI4aEVPS01ZN2hrZndGcURUWllfYUR1T1NZSXl4MDhhblJHazlWZGpXLW9rNzNEbW5iS3l3eHpRSUhIeTM0RU42MHN3TmZ3ZHlNVk5kVVdZbURVb3kySzlPYjVFUlN0VmdrTk1YUmdWb3p5LTczNHcwVWJTenZkdVJrdjlhamFEWlZ6QmhxQ2phVnVZc25xS2NDcVFCSy1NLWlWNWIxUUZ5VmF6dVNZMHZTYmR4dkdGdU1aWU1BdzMyclJWQQ?oc=5","date":"2023-05-14","type":"trial","source":"businesswire.com","summary":"Numab Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of NM26 Program - businesswire.com","headline":"Numab Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of NM26 Program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQUm5ObDZzbkFXeGpvdnVaR0xOeEZ4Y1lCSUgzYnQ5Y2N0Vm9HZkhDUkJaSm5fUm9vQ2FTVG5IeWlTdzJkWlNxYVVtMWMzSkV1N3oyUThuV2M0aUstLWhhaGZXem5mZmx5RTlHQmFzLU9ZMmpwUE94YlpUWlFYWGV4a1FDMDAzazVyd3pzVWpGZGxYNVcwa2lzUFVhWmU?oc=5","date":"2022-04-04","type":"deal","source":"Startupticker.ch","summary":"Numab signs a CHF 258 million deal with Ono Pharmaceuticles - Startupticker.ch","headline":"Numab signs a CHF 258 million deal with Ono Pharmaceuticles","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}